|Company||CryoCath Technologies, Inc.|
|Description|| CryoCath has developed a minimally invasive cryocatheter to treat atrioventricular nodal reentrant tachycardia. It delivers a very high level of safety through accurate site confirmation, pinpoint site precision, minimal tissue disruption, and minimal risk of thrombus and stenosis.
Freezor Xtra allows physicians to surgically treat cardiac arrhythmias in the pericardial space by minimally surgical techniques or during surgical cardiac procedures. It can be used in the subxyphoid approach to make lesions on the epicardial surface of the heart. In this procedure, the device is fed through a tiny incision just below the patient's sternum and advanced through an opening in the pericardial sac to reach the target epicardial location.
CryoAblation is well suited in the pericardial space as this area has no blood flow. Thanks to CryoAdhesion, the device tip sticks to the epicardium during the ablation procedure, resulting in enhanced stability.
Pre-clinical work has shown that Freezor Xtra is easily manipulated in the pericardial space and does not cause ay discernable damage to the coronary arteries when cryolesions are produced in close proximity to them.
|Info|| CryoCath Technologies, Inc.|
Customer Service: (877) 464-2796
Web site: http://www.cryocath.com